I want to point to the fact that because of our negotiations—and I am involved in these negotiations—we have been able to increase the number of doses that Canadians will receive this quarter by 3.5 million. This is as a result of, first, the agreement with the Serum Institute of India. Second, Pfizer agreed to accelerate 1.5 million doses from the second quarter to the first quarter as a result of our aggressive negotiations. Third, we have negotiated with the U.S. government for the delivery of 1.5 million AstraZeneca doses, which should arrive in Canada very shortly.
How do we do that? Because we are aggressive at the table. We want to make sure we have earlier and earlier doses for Canadians. We did that with Moderna prior to the holidays. We did that with Pfizer before the holidays and again in this quarter, and we did that with the Serum Institute and the U.S. government.
Our approach is that we will not stop negotiating aggressively to continue to see doses arriving in Canada. That's why we're going to see 36.5 million doses prior to Canada Day and 118 million doses from approved suppliers alone prior to the end of September, and we have another vaccine in rolling review with Health Canada—that's Novavax.
All in all, Mr. Chair, our diversified portfolio of vaccines continues to serve Canadians well. We did not bank on one vaccine from any one country. We put our eggs in multiple baskets, contrary to what the opposition continually says. We diversified our approach and can continue to serve Canadians with vaccines coming from multiple countries and multiple locations and multiple suppliers.